Antibody data
- Antibody Data
- Antigen structure
- References [4]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- ALX-804-064-C100 - Provider product page
- Provider
- Enzo Life Sciences
- Proper citation
- Enzo Life Sciences Cat#ALX-804-064-C100, RRID:AB_2051346
- Product name
- EGF receptor (human) monoclonal antibody (13G8)
- Antibody type
- Monoclonal
- Antigen
- Synthetic peptide
- Description
- Thiophilic adsorption and size exclusion chromatography purified.
- Reactivity
- Human, Mouse
- Host
- Mouse
- Isotype
- IgG
- Antibody clone number
- 13G8
- Vial size
- 100 μg
- Storage
- -20°C
- Handling
- Avoid freeze/thaw cycles. After reconstitution, prepare aliquots and freeze in liquid nitrogen.
Submitted references Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers.
RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells.
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer.
Y1068 phosphorylation is the most sensitive target of disulfonated tetraphenylporphyrin-based photodynamic therapy on epidermal growth factor receptor.
Misale S, Bozic I, Tong J, Peraza-Penton A, Lallo A, Baldi F, Lin KH, Truini M, Trusolino L, Bertotti A, Di Nicolantonio F, Nowak MA, Zhang L, Wood KC, Bardelli A
Nature communications 2015 Sep 22;6:8305
Nature communications 2015 Sep 22;6:8305
RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells.
Lamba S, Russo M, Sun C, Lazzari L, Cancelliere C, Grernrum W, Lieftink C, Bernards R, Di Nicolantonio F, Bardelli A
Cell reports 2014 Sep 11;8(5):1475-83
Cell reports 2014 Sep 11;8(5):1475-83
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer.
Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M, Siravegna G, Bencardino K, Cercek A, Chen CT, Veronese S, Zanon C, Sartore-Bianchi A, Gambacorta M, Gallicchio M, Vakiani E, Boscaro V, Medico E, Weiser M, Siena S, Di Nicolantonio F, Solit D, Bardelli A
Nature 2012 Jun 28;486(7404):532-6
Nature 2012 Jun 28;486(7404):532-6
Y1068 phosphorylation is the most sensitive target of disulfonated tetraphenylporphyrin-based photodynamic therapy on epidermal growth factor receptor.
Weyergang A, Selbo PK, Berg K
Biochemical pharmacology 2007 Jul 15;74(2):226-35
Biochemical pharmacology 2007 Jul 15;74(2):226-35
No comments: Submit comment
No validations: Submit validation data